GSK3B and Parkinson disease: In the HFD+NDEA group, both GSK-3β and pGSK-3β levels were reduced, but relative reductions were greater for pGSK-3β compared with total GSK-3β, reflecting a net relative increased in GSK-3β activity, similar to the findings in AD and PD in humans [29,30,104].